SCHEMBL5545365

SCHEMBL5545365

NC(=O)Nc1ccccc1[O]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.55
KDM4E B2RXH2 2/20 0.55
MAPT P10636 1/20 0.47
GFER P55789 1/20 0.47
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
RECQL P46063 1/20 0.46
POLB P06746 1/20 0.46
CYP1A2 P05177 1/20 0.46
LMNA P02545 2/20 0.42
MAPK1 P28482 2/20 0.42
TP53 P04637 1/20 0.42
HTT P42858 1/20 0.42
PEPD P12955 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
IKBKB O14920 1/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
TOP1 P11387 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29840068 0.87 GAA (0.67) GAAKDM4EMAPTGFERALDH1A1
SCHEMBL3928666 0.87 GAA (0.67) GAAKDM4EMAPTGFERALDH1A1
SCHEMBL4778316 0.82 KDM4E (0.42) GAAKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL10828925 0.81 RAB9A (0.45) MAPTALDH1A1SMN1; SMN2RECQLPOLB
SCHEMBL5635774 0.79 SMN1; SMN2 (0.40) GAAKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL958841 0.79 ALDH1A1 (0.63) KDM4EALDH1A1SMN1; SMN2POLBCYP1A2
SCHEMBL15259585 0.78 KDM4E (0.57) GAAKDM4EMAPTGFERALDH1A1
SCHEMBL7417077 0.78 GAA (0.57) GAAKDM4EMAPTGFERALDH1A1
SCHEMBL3859948 0.76 GAA (0.61) GAAKDM4EMAPTALDH1A1LMNA
SCHEMBL11760578 0.76 GAA (0.61) GAAKDM4EMAPTGFERALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 GAA 4165/4885KDM4E 4854/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.